Numinus expands its research lab, including more research space, supply capacity and accelerated IP development.
Numinus expands its research lab, including more research space, supply capacity and accelerated IP development.
Compass expecting to report data from its Phase IIb study by the end of 2021. Cash on hand decreases to $190.3 million, from $196.5 million the previous quarter.
Adelia Therapeutics, a subsidiary of Cybin Corp., achieves API synthesis and optimization on trypatmine derivatives.
Red Light Holland gets its VR "experience" hosted on the largest PC gaming platform.
This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform
MindMed raises CAD$19.5 million selling units at CAD$3.25.
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
ATAI announces closing its Series D financing round, raising $157 million.
The Company expects to have ibogaine manufactured and in use for research by Q4.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now